Talphera, Inc. (TLPH): Operating Cash Flow
-$11.36M
Year ended 2025-12-31
-$12.27M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$11.36M | n/m | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | -$12.68M | n/m | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | -$17.49M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | -$28.33M | n/m | 2024-03-06, From 2022-01-01 |
| 2021-12-31 | -$30.00M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$38.51M | n/m | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | -$51.18M | n/m | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | -$29.07M | n/m | 2021-03-15, From 2018-01-01 |
| 2017-12-31 | -$29.77M | n/m | 2020-03-16, From 2017-01-01 |
| 2016-12-31 | -$29.39M | n/m | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | -$19.95M | n/m | 2018-03-09, From 2015-01-01 |
| 2014-12-31 | -$34.46M | n/m | 2017-03-03, From 2014-01-01 |
| 2013-12-31 | -$487.0K | n/m | 2014-03-17, From 2013-01-01 |
| 2012-12-31 | -$24.58M | n/m | 2014-03-17, From 2012-01-01 |
| 2011-12-31 | -$15.29M | n/m | 2014-03-17, From 2011-01-01 |
| 2010-12-31 | -$12.22M | n/m | 2013-03-12, From 2010-01-01 |
| 2009-12-31 | -$19.42M | n/a | 2012-03-23, From 2009-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Talphera, Inc. (TLPH) | 2025-12-31 | -$11.36M | n/m |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | -$1.89M | n/m |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | -$5.41M | n/m |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | -$150.02M | n/m |
| Skinvisible, Inc. (SKVI) | 2025-12-31 | -$38.4K | n/m |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | -$20.36M | n/m |
| Altimmune, Inc. (ALT) | 2025-12-31 | -$67.53M | n/m |
| Bioadaptives, Inc. (BDPT) | 2025-12-31 | -$516.0K | n/m |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | -$3.96M | n/m |
Compare TLPH, IBO, JUNS, LYEL side by side · Screen every company in Pharmaceutical Preparations ↗